Exhibit 10.1

 

AMENDMENT #2 TO WARRANT AGREEMENT

 

ONCOBIOLOGICS, INC.

 

AND

 

AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, AS WARRANT AGENT

 

THIS AMENDMENT #2, dated February 9, 2018 (“Amendment #2”), to the Warrant
Agreement, dated as of May 18, 2016, as amended by that certain amendment dated
February 6, 2017 (the “Warrant Agreement”), by and between Oncobiologics, Inc.,
a Delaware corporation (the “Company”), and American Stock Transfer & Trust
Company, LLC, a New York limited liability trust company, as Warrant Agent (the
“Warrant Agent”).

 

WHEREAS, the Company and the Warrant Agent entered into that certain Warrant
Agreement relating to, among other things, the issuance of Series A warrants to
purchase shares of the Company’s common stock at an exercise price of $6.60 per
share (the “Series A Warrants”); and

 

WHEREAS, pursuant to Section 8.9 of the Warrant Agreement, the Company and the
Warrant Agent have agreed to further amend the Warrant Agreement to further
extend the period for exercising the Warrants from February 18, 2018 to February
18, 2019.

 

NOW, THEREFORE, in consideration of the mutual agreements herein contained, the
Company and the Warrant Agent agree as follows:

 

1.Amendments.

 

a.Section 3.3.1 of the Warrant Agreement is amended and restated as follows:

 

  “3.3.1

Series A Warrants. Each Series A Warrant may be exercised, in whole or in part,
at any time during the period commencing on the Detachment Date and ending at
5:00pm New York City time on the earlier to occur of (a) the date that is twenty
(20) business days after the date on which the Closing Sales Price of the Common
Stock is greater than or equal to $7.25 per share and (b) February 18, 2019.”

 

b.The first sentence of Section 3.3.3 of the Warrant Agreement is amended and
restated as follows:

 

“For purposes of this Agreement, the term “Expiration Date” means the earlier to
occur of (a) the date that is twenty (20) business days after the date on which
the Closing Sales Price of the Common Stock is greater than or equal to $7.25
per share and (b) February 18, 2019 with respect to the Series A Warrants; and
May 18, 2018 with respect to the Series B Warrants; and the term “Exercise
Period” means the period during which the Series A Warrant or Series B Warrant,
as the case may be, is exercisable, as described in subsection 3.1, 3.3.1 or
3.3.2 hereof.”

 

2.Counterparts. This Amendment may be executed in any number of original or
facsimile counterparts and each of such counterparts shall for all purposes be
deemed to be an original, and all such counterparts shall together constitute
but one and the same instrument.

 

[Signature page follows]

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment #2 to be duly
executed as of the date first above written.

 

  COMPANY:       Oncobiologics, Inc.         By: /s/ Lawrence A. Kenyon    
Name: Lawrence A. Kenyon     Title: Chief Financial Officer       WARRANT AGENT:
      American Stock Transfer & Trust Company, LLC         By: /s/ Jennifer
Donovan     Name: Jennifer Donovan     Title: Senior Vice President